Abstract Background. Epstein-Barr virus (EBV)-associated post-transplantation Iymphoproliferative disease (PTLD) develops in 1 to 10 percent of transplant recipients, in whom it can be treated by a reduction in the level of immunosuppression. We postulated that the tissue expression of the small RNA transcribed by the EBER-1 gene during latent EBV infection would identify patients at risk for PTLD.
Abstract Background. Epstein-Barr virus (EBV)-associated post-transplantation Iymphoproliferative disease (PTLD) develops in 1 to 10 percent of transplant recipients, in whom it can be treated by a reduction in the level of immunosuppression. We postulated that the tissue expression of the small RNA transcribed by the EBER-1 gene during latent EBV infection would identify patients at risk for PTLD.
Methods. We studied EBER-1 gene expression in liver specimens obtained from 24 patients 2 days to 22 months before the development of PTLD, using in situ hybridization with an oligonucleotide probe. Control specimens were obtained from 20 recipients of allografts with signs of injury due to organ retrieval, acute graft rejection, or viral hepatitis in whom PTLD had not developed 9 to 71 months after the biopsy. Immunohistochemical studies have demonstrated that the lymphoid cells within the lesions of PTLD almost invariably contain Epstein-Barr virus (EBV), primarily in a state of laten t infection. 4 ,5 The EBER-I gene is expressed early during latent EBV infection and codes for a small messenger RNA (mRNA) expressed at up to 10 7 copies per eel\. 6 We and others have previously demonstrated the value of the detection of EBER-I RNA for identifying EBVinfected cells in formalin-fixed paraffin-embedded tissues. 7 ,8 In the current investigation, we used in situ hybridization to examine a series of liver-biopsy specimens from pediatric liver recipients in whom PTLD developed, as well as a control group of patients in whom this disorder did not develop, for evidence of cells expressing the EBER-I gene. We found that such expression may permit early identification of patients at risk for PTLD. identified 24 liver recipients who met the two criteria for entry to our study: PTLD had been diagnosed histopathologically,3 and at least one liver-biopsy specimen obtained before the diagnosis of PTLD was available for evaluation, Control patients were drawn from the same files as the patients with PTLD. The controls had had no docum ented PTLD during a follow-up period of at least nine months after the performance of the liver biopsy yielding a specimen selected to serve as a control. Pertinent clinical information about the group with PTLD and the control group was obtained from medical records. Histopathological evaluation of the liver specimens selected for study was performed on 4-p,m sections of tissue routinely embedded in paraffin and stained with hematoxylin and eosin.
The in situ hybridization studies of EBV RNA were performed with a 30-base digoxigenin-Iabeled oligonucleotide complementary to a portion of the EBER-I gene. The details of the technique have been published elsewhere. s Th e appearance of a brown or bluebrown color in the nucleus was considered a positive reaction. This method has previously detected EBV RNA from an EBV-infected Raji-celiline, but does not detect EBV in the T-cell line Molt, whi ch does not contain EBV. Lymphoid tissue from an EBV-seronegative patient and tissues infected with herpes simplex virus type I , papillomavirus type 16, and adenovirus showed no cross-reactivity. Tis· sue from a patient with PTLD who was known to be positive for EBV served as a positive control in each run. Any slide negative for EBV RNA was tested for preservation of RNA with th e use of a polydeoxythymidine probe 9 ,tO The frequency of EBV -infected cells was determined in a semiquantitative fashion by counting the total number of EBER-l cells in relation to the total number of lymphocytes seen in parallel sections prepared from the same biopsy specimen and stained with hematoxylin and eosin. The cells in the hepatic sinusoids and portal tracts were counted. In small specimens, all available cells were counted; in larger specimens, every second o( third portal tract was exa mined .
Immunohistochemical in situ hybridization studies with double labeling were performed on liver blocks obtained at autopsy f(Om four patients with fatal PTLD. Initially, the immunohistochemical reaction was performed according to a previously published meth- tChanges reflecting graft rejection and ischemic injury were frequently concurrent. §Hepalitis was albibuted to cytomegalovirus or non-A, non-8 hepatitis virus in Ihe control group. and generally 10 EBY in !he group wilh PTLD. The latter group included five patients with COllCWTeot hepatitis and rejection (see !he leX! [01' detailed histopathological findings).
Calif.), and GN-2 (Enzo Biochemicals, New York). Thereafter, in situ hybridization studies were performed as outlined above.
REsULTS
The group with PTLD comprised 10 male and 14 female patients. Their ages at the time of transplantation ranged from 6 months to 25 years (median, 3.7 years). Their diagnoses included a variety of liver disorders, such as biliary atresia, cryptogenic cirrhosis, alphal-antitrypsin deficiency, hereditary cholestasis, and hyperalimentation injury. One patient had received a heart transplant for idiopathic cardiomyopathy. The onset of PTLD occurred a median of 12.5 weeks after transplantation (range, 5 to 640). The anaro mical sites involved by PTLD when it was first diagnosed were the liver (seven patients), the tonsils or adenoids (five patients), the gastrointestinal tract (five patients) , the trachea (one patient), the bile duct (one pa tient), the meninges (one patient), and the lymph nodes (one patient); in three patients the disease was d issemina ted.
T he con trol group consisted of 12 male and 8 female pa tients 10 months to 16 years old (median, 7 years). T he spe trum of primary diseases requiring transplantation in this group was similar to that in the group with PTLD. The biopsy specimens selected as controls were obtained 5 to 1790 days after transplanta tion (median, 27.5). Histopathological examination generally showed varying degrees of cellular rejection with or without injury due to organ retrieval, as assessed by standard criteria. 12 Two controls had non-A, non-B hepatitis, and three had cytomegalovirus hepatitis (Table I) . These controls had no evidence of PTLD during clinical follow-up lasting 9 to 71 months after liver biopsy (median, 30).
In si tu hybrid ization studies for EBER-I expression revealed tha t in 17 of the 24 patients with PTLD (7 1 percent), one or more Hver specimens obtained before the development of PTLD contained from 1 percent to 40 percent EBER-I mRNA-positive mononuclear cells in the portal tracts and sinusoids ( Fig. I and 2 ). In contrast, only 2 of 20 controls (10 percent) had mononuclear cells containing EBER-I mRNA (P<O.OOI by Fisher's exact test); in both these controls, less than 1 percent of the cells were positive. Generally, the positive cells were small lymphocytes, although some were as large as 20 IJ-m . Hepatocytes, bile-duct epithelial cells, and endothelial cells did not hybridize with the EBER-I probe. In the group with PTLD, the interval between the detection of EBER-I mR:'~A in mononuclear cells and the development of PTLD ranged from 0 to 50 days in 10 patients and from 51 to 100 days in 3 patients; it was more than 100 days in 4 patients. In I of these 17 patients, rare EBER-I mRNA-positive cells were detected 660 days before the onset of PTLD. In 10 of the 17 patients in whom EBV-positive cells were identified, the subsequent PTLD involved the liver, whereas in the other 7 patients it involved other organs. Expression of the EBER-I gene could be demonstrated in each of II specimens of tissue involved by PTLD that were studied by in situ hybridization (Fig. 3) . These tissues contained abundant EBER-I-positive mononuclear cells, which accounted for more than 80 percent of the total lymphoid-cell population in some patients. Small round lymphocytes as well as cells with blastic transformation contained EBV mRNA. As in three previously reported cases of PTLD,13 rare hepatocytes also showed staining for EBER-I mRNA (Fig.  4) . Bile-duct epithelial cells and endothelial cells were negative in all patients . Double-labeling studies showed that the majority of the lymphoid cells positive for EBER-I mRNA had membranes positive for CD20, .a finding consistent with B-celilineage (Fig.  5) . However, cells coexpressing CD43 and EBER-I mRNA, presumably representing T cells, were also present in small numbers. Serologic data temporally related to the biopsy were obtained for 16 of the 24 patients with PTLD (through the courtesy of Dr. M .C. Breinig, University of Pittsburgh). Six patients were judged either to be seronegative for EBV or to have titers transiently positive for EBV because of multiple perioperative blood transfusions; all were negative for EBER-I mRNA. The other 10 patients were seropositive and found to be positive for EBER-I m RNA as well. Serologic d a ta were available for 15 of the 20 controls_ Both EBER-I-positi e controls were seropositive for EB ; one was undergoing primary seroconversion a t the time of biopsy. Five con trols were seropositive for EBV b ut EBER-I -negative. The eigh t other controls were seronegative as well as EBER-I-negative.
Histopa thological examination. of liver specimens from the 17 patients wi th PT LD whos mononuclear cells were positi e for EBER-I mRNA showed that 15 patien ts had cha nges ind icating EBV hepa ti tis, consis ti ng of activa ted mononuclear infiltrates in the portal tracts associa ted with lob ul ar d isarray and sin usoidal lym phocytes arranged in linea r beads and small aggregates. One patient had mononuclear infla mmatory infiltrates that spared the porta l tracts a nd resembled lobular hepatitis. Five patients, in ad d ition to the changes of EBV hepatitis , had a mixed lymphocytic, polymorphonuclear, and eosinophilic portal-tract infiltrate associa ted with bile-duct injury, indicating a mild acute cellular rejection. One patient had a necrotizing granulomatous hepatitis with adenovirus inclusions. When PTLD supervened in the patients with EBV hepatitis, the mononuclear-cell infiltrates expanded and acquired atypical nuclear characteristics.
Liver specimens obtained from 7 of the 24 patients before PTLD developed were negative for EBER-I mRNA. The histologic correlates of these tissues were mild acute cellular rejection with or without coexisting injury due to organ retrieval (five patients) or injury due to hyperalimentation (one patient); nonspecific changes consisting of mild hepatocellular swelling with scattered polymorphonuclear leukocytes and lymphocytes in the sinusoids were observed in one patient (Table I ) . DISCUSSION The oropharyngeal mucosa, parotid and lacrimal glands, lymph nodes , and circulating lymphocytes are known to be anatomical sites where latent EBV may persist after acute infectious mononucleosis 8 , 14-17 The present study indicates that lymphocytes of the hepa tic portal tract and sinusoids can also har bor EBV, and that an increase in the number of EBER-l-positive cells precedes clinically and histologically evident PTLD. The detection of such EBV-positive cells in the absence of evidence of graft rej ection should prompt the physician to consider decreasing the level of immunosuppression, since EBV infections , even when PTLD is advanced, are responsive to imm unomodulation.
2 Prospective studies will be necessary to assess the positive predictive value of EBE R-I-positive cells in regard to the possible development of PTLD in a particular patient.
The presence of EBV-positive lymphoid cells before the occurrence of lymphoproliferative dis ase has also been observed in lymph nodes from pa tients with the acquired immunodeficiency syndrome; this fi nding is consistent with current notions of a multistep process of carcinogenesis induced by EBV.
18 - 21 The possible role of EBER-I mRNA in the evolution of PTLD is unknown, bu t it has been suggested that E BER-I genes direct the synthesis of critical viral proteins in vivoY . The fac t that EBV-positive cells in PTLD lesions Immunohistochemical evaluation with anti-CD20 antibody, combined with in situ hybridization, showed that in PTLD the majority of EBV-infected lymphocytes are B cells. Cells positive for CD20 are stained brown, and those positive for EBER-1 mRNA are stained blue-black.
Dec. 10, 1992 were generally positive for CD20 is consistent with the notion that the EBV receptors required for the virus to enter the cells are normally found on B cells. 23 The less frequent occurrence of EBER-l mRNA in CD43-positive cells adds to growing evidence that benign as well as neopla stic T ells can occasionally be infected with EBV .8,24,25 Several authors have described the histopathological features of clini cally presumed EBV hepatitis in patients who were not graft recipients 26 .
28 and in recipients of liver allografts . 29 O ur study documents the presence of EBV -infected cells in the liver tissue of tra nsplant recipients . EBV hepatitis in liver allografts may be overlooked if the pathologist does not pay close attention to lobu lar disarray and sin usoidallymphocytosis. The demonstration of the presence of a virus by in situ hybridizat ion is very helpful in reaching a diagnosis when mononuclear infiltrates are subtle, but it is unnecessary when numerous transformed lymphocytes can be clearly seen within the sinusoids, arra nged in d iscrete aggregates and linear chains. Howev r, serologic data should be obtained in the latter case, sin e non-A, non-B hepatitis can cause similar changes 3 0 We a re inde bted to Professo r Monto Ho a nd Dr. Mary C . Breinig (Department o f Infectious Disea",' and Microbiology , University of Pittsburgh ) for pro viding the serologic findings about EBV statu s.
